These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 34490338)

  • 1. Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Chen D; Jin Z; Zhang J; Xu C; Zhu K; Ruan Y; Zhang B; Chen B; Shen J
    Front Surg; 2021; 8():715318. PubMed ID: 34490338
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy, safety, and survival of neoadjuvant immunochemotherapy in operable non-small cell lung cancer: a systematic review and meta-analysis.
    Zheng Y; Feng B; Chen J; You L
    Front Immunol; 2023; 14():1273220. PubMed ID: 38106421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemoradiotherapy or chemotherapy followed by surgery is superior to that followed by definitive chemoradiation or radiotherapy in stage IIIA (N2) nonsmall-cell lung cancer: a meta-analysis and system review.
    Xu XL; Dan L; Chen W; Zhu SM; Mao WM
    Onco Targets Ther; 2016; 9():845-53. PubMed ID: 26955282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Efficacy and Safety of Neoadjuvant Immunotherapy in Patients with Non-Small Cell Lung Cancer.
    Guven DC; Sahin TK; Kilickap S
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indirect comparison of the efficacy and safety of gefitinib and cetuximab-based therapy in patients with advanced non-small-cell lung cancer.
    Tang J; Zhang H; Yan J; Shao R
    Mol Clin Oncol; 2015 Jan; 3(1):145-150. PubMed ID: 25469285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of patients taking first-generation EGFR-TKIs may predict the benefits afforded by osimertinib in EGFR T790M-mutant NSCLC patients.
    Meng H; Huang L; Wang J; Zhou Y; Wang M; Yang Z; Hong X
    Int J Clin Pract; 2021 Dec; 75(12):e14877. PubMed ID: 34525256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction Model for Tumor Volume Nadir in EGFR -mutant NSCLC Patients Treated With EGFR Tyrosine Kinase Inhibitors.
    Nishino M; Lu J; Hino T; Vokes NI; Jänne PA; Hatabu H; Johnson BE
    J Thorac Imaging; 2023 Mar; 38(2):82-87. PubMed ID: 34524205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance.
    Finlay MRV; Barton P; Bickerton S; Bista M; Colclough N; Cross DAE; Evans L; Floc'h N; Gregson C; Guérot CM; Hargreaves D; Kang X; Lenz EM; Li X; Liu Y; Lorthioir O; Martin MJ; McKerrecher D; McWhirter C; O'Neill D; Orme JP; Mosallanejad A; Rahi A; Smith PD; Talbot V; Ward RA; Wrigley G; Wylot M; Xue L; Yao T; Ye Y; Zhao X
    J Med Chem; 2021 Sep; 64(18):13704-13718. PubMed ID: 34491761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma.
    Wang S; Xie T; Hao X; Wang Y; Hu X; Wang L; Li Y; Li J; Xing P
    Thorac Cancer; 2021 Oct; 12(19):2585-2593. PubMed ID: 34490724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation.
    Cardona AF; Jaramillo-Velásquez D; Ruiz-Patiño A; Polo C; Jiménez E; Hakim F; Gómez D; Ramón JF; Cifuentes H; Mejía JA; Salguero F; Ordoñez C; Muñoz Á; Bermúdez S; Useche N; Pineda D; Ricaurte L; Zatarain-Barrón ZL; Rodríguez J; Avila J; Rojas L; Jaller E; Sotelo C; Garcia-Robledo JE; Santoyo N; Rolfo C; Rosell R; Arrieta O
    J Neurooncol; 2021 Sep; 154(3):353-364. PubMed ID: 34498213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases.
    Lauko A; Kotecha R; Barnett A; Li H; Tatineni V; Ali A; Patil P; Mohammadi AM; Chao ST; Murphy ES; Angelov L; Suh JH; Barnett GH; Pennell NA; Ahluwalia MS
    Sci Rep; 2021 Sep; 11(1):18174. PubMed ID: 34518623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revisiting neoadjuvant therapy in non-small-cell lung cancer.
    Saw SPL; Ong BH; Chua KLM; Takano A; Tan DSW
    Lancet Oncol; 2021 Nov; 22(11):e501-e516. PubMed ID: 34735819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment.
    Friedlaender A; Subbiah V; Russo A; Banna GL; Malapelle U; Rolfo C; Addeo A
    Nat Rev Clin Oncol; 2022 Jan; 19(1):51-69. PubMed ID: 34561632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy Should Be Combined With Checkpoint Inhibitors in the Treatment of Patients With Stage IV EGFR-Mutant NSCLC Whose Disease Has Progressed on All Available Tyrosine Kinase Inhibitors.
    Zhou F; Zhou C
    J Thorac Oncol; 2021 Oct; 16(10):1622-1626. PubMed ID: 34561035
    [No Abstract]   [Full Text] [Related]  

  • 15. Two cases of non-small cell lung cancer patients with somatic or germline EGFR R776H mutation.
    Guo T; Zhu L; Li W; Lin R; Ding Y; Kang Q; Shao L; Li C; Pan X
    Lung Cancer; 2021 Nov; 161():94-97. PubMed ID: 34555730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
    Felip E; Altorki N; Zhou C; Csőszi T; Vynnychenko I; Goloborodko O; Luft A; Akopov A; Martinez-Marti A; Kenmotsu H; Chen YM; Chella A; Sugawara S; Voong D; Wu F; Yi J; Deng Y; McCleland M; Bennett E; Gitlitz B; Wakelee H;
    Lancet; 2021 Oct; 398(10308):1344-1357. PubMed ID: 34555333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Prognosis of First-Line EGFR-Tyrosine Kinase Inhibitor Treatment in Older Adults Including Poor Performance Status Patients with
    Chang CY; Chen CY; Chang SC; Lai YC; Wei YF
    Cancer Manag Res; 2021; 13():7187-7201. PubMed ID: 34552354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study.
    Planchard D; Feng PH; Karaseva N; Kim SW; Kim TM; Lee CK; Poltoratskiy A; Yanagitani N; Marshall R; Huang X; Howarth P; Jänne PA; Kobayashi K
    ESMO Open; 2021 Oct; 6(5):100271. PubMed ID: 34543864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS and BRAF Mutations in Stage II and III Colon Cancer: A Systematic Review and Meta-Analysis.
    Formica V; Sera F; Cremolini C; Riondino S; Morelli C; Arkenau HT; Roselli M
    J Natl Cancer Inst; 2022 Apr; 114(4):517-527. PubMed ID: 34542636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.
    Camidge DR; Kim HR; Ahn MJ; Yang JCH; Han JY; Hochmair MJ; Lee KH; Delmonte A; Garcia Campelo MR; Kim DW; Griesinger F; Felip E; Califano R; Spira AI; Gettinger SN; Tiseo M; Lin HM; Liu Y; Vranceanu F; Niu H; Zhang P; Popat S
    J Thorac Oncol; 2021 Dec; 16(12):2091-2108. PubMed ID: 34537440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.